Related Experiment Video
Updated: Dec 3, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.1K
Peptidomics Analysis Reveals Peptide PDCryab1 Inhibits Doxorubicin-Induced Cardiotoxicity
Li Zhang1, Xuejun Wang1, Mengwen Feng1
1Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Oxidative Medicine and Cellular Longevity
|October 28, 2020
Summary
Doxorubicin (DOX) causes heart damage, but this study identified specific peptides that may protect the heart. A peptide from Cryab showed promise in preventing DOX-induced cardiotoxicity.
Area of Science:
- Proteomics
- Cardiology
- Peptidomics
Background:
- Doxorubicin (DOX) chemotherapy is limited by dose-dependent cardiotoxicity.
- Endogenous peptides are crucial in biological processes and potential drug candidates.
- Peptidomics offers insights into peptide changes and therapeutic targets.
Purpose of the Study:
- To investigate peptide expression changes in DOX-induced cardiotoxicity.
- To identify novel cardioprotective peptides for therapeutic development.
- To explore potential treatments for Doxorubicin-induced heart damage.
Main Methods:
- Comparative peptidomics analysis of heart tissue from DOX-treated and control mice using mass spectrometry.
- Bioinformatics analysis to predict cardioprotective potential of identified peptides.
- In vitro and in vivo validation of a specific cardioprotective peptide (SPFYLRPPSF).
Main Results:
- 236 differential peptides were identified in DOX-treated hearts (22 upregulated, 214 downregulated).
- 31 peptides were predicted to have cardioprotective functions.
- The peptide SPFYLRPPSF demonstrated inhibition of cardiomyocyte apoptosis, reduced reactive oxygen species, improved cardiac function, and ameliorated myocardial fibrosis.
Conclusions:
- DOX treatment significantly alters cardiac peptide expression profiles.
- Differentially expressed peptides hold potential for treating DOX-induced cardiotoxicity.
- The identified peptide SPFYLRPPSF shows significant cardioprotective effects, suggesting a new therapeutic strategy.
